NT-proBNP in chronic hypercapnic respiratory failure: A marker of disease severity, treatment effect and prognosis

Budweiser, Stephan and Luchner, Andreas and Jorres, Rudolf A. and Heinemann, Frank and Hitzl, Andre P. and Schmidbauer, Kathrin and Riegger, Gunter and Pfeifer, Michael (2007) NT-proBNP in chronic hypercapnic respiratory failure: A marker of disease severity, treatment effect and prognosis. RESPIRATORY MEDICINE, 101 (9). pp. 2003-2010. ISSN 0954-6111, 1532-3064

Full text not available from this repository. (Request a copy)

Abstract

Background: Natriuretic peptides are considered as reliable indicators of left-heart failure (HF) and are useful for differential diagnosis of dyspnoea. Aim: We evaluated the clinical significance of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with chronic hypercapnic respiratory failure (CHRF). Methods: In 60 patients with CHRF, plasma concentrations of NT-proBNP were assessed at baseline and after treatment including non-invasive ventilation (NIV). The relationship of NT-proBNP to disease severity and its predictive value for survival were evaluated up to 4 years. Results: NT-proBNP levels were markedly elevated in patients with CHRF (n = 60; geometric mean (SD) 546.4 (4.9) pg/mL; p < 0.001) compared to healthy controls (n = 182; 49.0 (2.2) pg/mL). After excluding patients with concomitant HF or renal impairment, levels were still increased (n=43; 393.2 (3.8) pg/mL; p < 0.001). According to multivariate regression, hypoxia and exacerbation independently determined NT-proBNP levels (p < 0.05 each). After initiation of NIV, blood gases and lung function improved and NT-proBNP decreased (-31.3 (0.3)%; p < 0.001). During 22.5 (2.2) months follow-up, NT-proBNP was not significantly associated with survival in the total population, however, the subgroup of patients with levels > 722pg/mL (67th percentile) and no adherence to NIV displayed poor prognosis (hazard ratio = 0.21; 95%-CI = 0.022-0.580; p = 0.0091). Conclusions: NT-proBNP was highly elevated in patients with CHRF and correlated with the degree of respiratory impairment and exacerbation. Correspondingly, treatment including NIV led to reduction of NT-proBNP These data indicate a potential role of NTproBNP in assessing disease severity, treatment efficacy and prognosis in CHRF. (c) 2007 Elsevier Ltd. All rights reserved.

Item Type: Article
Uncontrolled Keywords: BRAIN NATRIURETIC PEPTIDE; NONINVASIVE MECHANICAL VENTILATION; PULMONARY ARTERIAL-HYPERTENSION; HEART-FAILURE; LUNG-DISEASE; SYSTEMIC-SCLEROSIS; COR-PULMONALE; DYSPNEA; BNP; DYSFUNCTION; brain natriuretic peptide; chronic respiratory failure; congestive heart failure; non-invasive ventilation; right ventricular overload; survival
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin II
Depositing User: Dr. Gernot Deinzer
Date Deposited: 01 Dec 2020 10:44
Last Modified: 01 Dec 2020 10:44
URI: https://pred.uni-regensburg.de/id/eprint/32333

Actions (login required)

View Item View Item